tiprankstipranks
Trending News
More News >

Patrys Limited Refocuses on Promising PAT-DX3 Antibody

Patrys Limited Refocuses on Promising PAT-DX3 Antibody

Patrys Limited (AU:PAB) has released an update.

Confident Investing Starts Here:

Patrys Limited has announced a shift in its clinical development strategy, moving away from PAT-DX1 due to production challenges and potential safety concerns. The company will concentrate its efforts on PAT-DX3, an antibody with higher yield and stability, which is poised for commercial scale production. Patrys aims to leverage its existing data to explore co-development and licensing partnerships for PAT-DX1, while also investigating the potential of deoxymabs in inflammatory conditions.

For further insights into AU:PAB stock, check out TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App